Aligos (ALGS) files 8-K, furnishes Exhibit 99.1 press release

Aligos Therapeutics (ALGS) reported it furnished a press release via an 8-K under Item 2.02 (Results of Operations and Financial Condition) on November 6, 2025.

Accepted by SEC EDGAR 11/06/2025 - 08:30 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aligos Therapeutics (ALGS) reported it furnished a press release via an 8-K under Item 2.02 (Results of Operations and Financial Condition) on November 6, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference in the report.

The company states the information under Item 2.02 and Exhibit 99.1 is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act, and it will not be incorporated into other filings unless expressly referenced. Aligos’ common stock trades on the Nasdaq Capital Market under the symbol ALGS.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aligos Therapeutics (ALGS) announce in this 8-K?

Aligos furnished a press release under Item 2.02 (Results of Operations and Financial Condition), attached as Exhibit 99.1.

Is the Item 2.02 information deemed filed under the Exchange Act?

No. The Item 2.02 information and Exhibit 99.1 are being furnished, not filed, and are not subject to Section 18 liabilities.

What exhibit accompanies the 8-K for ALGS?

The filing includes Exhibit 99.1, a press release dated November 6, 2025.

Where is Aligos Therapeutics listed and under what ticker?

Aligos’ common stock trades on the Nasdaq Capital Market under the symbol ALGS.

Who signed the report for Aligos Therapeutics?

The report was signed by Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer and Chief Financial Officer.

Does the 8-K incorporate the press release into other filings?

It will not be incorporated by reference into other filings unless expressly set forth by specific reference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

False000179944800017994482025-11-062025-11-06iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 6, 2025

_______________________________

Aligos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-39617	82-4724808
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

One Corporate Dr., 2nd Floor

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(800) 466-6059

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	ALGS	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

99.1		Press Release dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aligos Therapeutics, Inc.
Date: November 6, 2025	By:	/s/ Lesley Ann Calhoun
		Lesley Ann Calhoun
		Executive Vice President, Chief Operating Officer and Chief Financial Officer